₹1,600 Crore Approved for 41 Pharma & MedTech Innovation Projects under PRIP First Round

1. At a Glance

• The Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) is a ₹5,000 crore scheme. It aims to move Indian pharma from cost-based to innovation-based growth [2][4].
• Under the first call, 41 projects got about ₹1,600 crore in assistance. They are expected to bring in ₹3,020 crore of private investment, for a total R&D spend of about ₹4,620 crore [1].
• It matters for UPSC because it links industrial policy, health security (AMR, TB, pandemics), start-ups/MSMEs and S&T (GS-III), and health policy (GS-II).

2. Why in the News

• 30 Sep 2026: The Department of Pharmaceuticals announced the approval of 41 PRIP first-call projects worth about ₹1,600 crore [1].
• Six projects were approved under the Strategic Priority framework. They cover bacterial pneumonia/meningitis, dengue, influenza and next-generation TB vaccines [1].
• Evaluation of the other first-round applications is still going on. More results are due "over the coming month" [1].

3. Background & Evolution

• Rationale: Build research infrastructure, promote industry–academia linkage in priority R&D areas, and create a culture of quality research [4].
• Launch: Dr Mansukh Mandaviya launched PRIP together with the National Policy on Research and Development and Innovation in Pharma-MedTech Sector [3]. (The exact release date was not retrieved; the press release number points to 2023. Verify before quoting.)
• Component A: Foundation stones were laid for four Centres of Excellence (CoEs), at NIPER Ahmedabad, Hyderabad, Guwahati and Mohali, by the Prime Minister [7].
• 2025: DoP held a PRIP workshop and an industry dialogue in Bengaluru [8].
• 1 Oct 2025: The amended scheme was notified, to give clearer governance and better benefit-sharing [5]. On the same date, the application window opened on the PRIP portal (prip.pharma-dept.gov.in) [6].
• 19 Nov 2025: The first call closed with 710 project applications from industry, start-ups and MSMEs [5].
• 2026: A second call for applications was announced under the ₹5,000 crore scheme [9].
• 30 Sep 2026: First-round approvals were announced (41 projects) [1].

4. Core Static Facts

CoEs under Component A [5]:

• NIPER Mohali (Punjab): ₹100 crore
• NIPER Ahmedabad (Gujarat): ₹110 crore
• NIPER Guwahati (Assam): ₹100 crore
• NIPER Kolkata (WB): ₹100 crore
• NIPER Raebareli (UP): ₹100 crore
• NIPER Hajipur (Bihar): ₹99.99 crore
• NIPER Hyderabad (Telangana): ₹90 crore
• CoE specialisations: anti-viral/anti-bacterial drug discovery, medical devices, bulk drugs, flow chemistry and continuous manufacturing, novel drug delivery systems, phyto-pharmaceuticals, biological therapeutics [5]

First-round portfolio (41 projects) [1]:

• By stage: 12 early-stage, 29 later-stage
• By applicant: 19 start-ups/MSMEs, 22 large companies
• By area: 27 New Medicines, 5 Complex Generics & Biosimilars, 9 Novel Medical Devices
• Strategic Priority projects: 6
• Named firms: Biocon, Bharat Biotech, Sun Pharma, Wockhardt, Zydus, Mankind Pharma, Pandorum Technologies, Cellogen Therapeutics, Aurigene Oncology, Bugworks Research

5. Multi-Dimensional Analysis

Economic

• Leverage: ₹1,600 crore of public money is expected to bring in ₹3,020 crore of private money. That is about ₹1.9 of private money per public rupee, so the government funds roughly 35% of total R&D spend [1] (computed).
• It signals a shift from a volume-driven to an innovation-led, technology-intensive pharma model [1].
• Big gap between demand and approvals: 41 approved so far out of 710 first-call applications (~6%) [1][5]. Evaluation is still ongoing.

Scientific / Technological

• Frontier technologies are funded, including [1]:
• in-vivo CAR-T platform
• exosome-based corneal regenerative therapy
• patient-derived breast-cancer organoids
• programmable RNA-targeting antiviral
• portable plasmonic-PCR

• microfluidic TB detection

• Support is classified into four categories: first-in-class, emerging technologies, global-market potential, and strategic priority innovations [1].

Social / Public Health

• The SPI framework gives enhanced support for neglected tropical diseases, rare diseases, AMR for India-priority pathogens, outbreak/pandemic pathogens, and vaccines [1].
• Relevant approved projects include an antibacterial against multidrug-resistant Gram-negative infections, and dengue, influenza and TB vaccine projects [1].

Governance / Administrative

• Applications are fully digital through the PRIP portal [6]. The 2025 amendment aimed at clearer governance and benefit-sharing [5].
• The scheme plans a pan-India digital Pharma-MedTech innovation exchange. It would link innovators with investors, mentors and government initiatives such as Patent Mitra and MedTech Mitra [5].

Strategic

• It builds domestic capacity in vaccines and pandemic-pathogen countermeasures, supporting Atmanirbhar Bharat in pharma [1][10].

6. Recent Developments (last 12–18 months)

• 1 Oct 2025: Amended PRIP scheme notified; portal application window opened [5][6].
• 19 Nov 2025: First call closed with 710 applications [5].
• 2026: Second call for applications announced [9].
• 30 Sep 2026: 41 projects approved (₹1,600 crore of assistance; ₹4,620 crore total R&D); 6 SPI projects approved [1].

7. Prelims Hooks

• PRIP is run by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, not MoHFW [1].
• Total PRIP outlay: ₹5,000 crore [4].
• Component A: 7 CoEs at 7 NIPERs, about ₹700 crore [4].
• Component B: ₹4,250 crore for industry and start-up research projects [4].
• Largest CoE allocation: NIPER Ahmedabad (₹110 crore). Smallest: NIPER Hyderabad (₹90 crore) [5].
• Later-stage assistance: 35% of project cost, max ₹100 crore; 50% for Strategic Priority Innovation areas [4][6].
• Early-stage assistance for MSMEs/start-ups: max ₹5 crore [4].
• First-call approvals: 41 projects, ₹1,600 crore; total R&D ₹4,620 crore [1].
• New Medicines was the largest share (27 of 41) [1].
• 19 of 41 projects are by start-ups/MSMEs [1].
• Six projects approved under the Strategic Priority framework [1].
• Amended PRIP scheme notified on 1 Oct 2025 [5].
• The scheme targets about 300 projects and about ₹11,000 crore of R&D investment [4].

8. Why a Grant Alone May Not Bring a New Antibiotic to Market

• PRIP pays for research. It does not pay for the medicine once it is made.
• There are two ways to reward drug research. A push incentive (money given up front to pay for research) lowers the cost of trying. A pull incentive (a reward paid only when a finished product reaches patients) makes sure there is income at the end [14].

• PRIP is a push incentive. Its grant covers 35–50% of a project's cost [4][6].

• New antibiotics have almost no market, even when they work

• Doctors are told to keep a new antibiotic in reserve and use it only when older drugs fail. This slows resistance, but it also means very few doses are sold.
• For this reason, WHO's 2024 report on G7 countries says pull incentives must be sped up and strengthened. Push money alone has not filled the antibiotic pipeline [14].

• The same WHO report says the world needs an extra US$250–400 million a year to keep antibiotic development going [14].

• This risk falls directly on PRIP's AMR projects

• Round 1 funds an antibacterial against multidrug-resistant Gram-negative infections (infections from a group of bacteria that many antibiotics cannot kill) [1].

• PRIP can help such a drug reach approval. After that, the company still needs buyers, and nothing in the scheme promises them.

• The UK pays for having an antibiotic available, not for how much is sold

• The NHS in England buys certain new antibiotics under a subscription. It pays a fixed fee whether many or few doses are used, so the company's income no longer depends on sales volume [15].
• India has no such payment model for new antibiotics. PRIP's AMR bets could stall after approval because there is no buyer.

9. What the First-Round Money Leaves for Everyone Else

• Round 1 has already used a large share of the industry budget
• Component B has ₹4,250 crore for industry and start-up projects [4].

• Round 1 approved ₹1,600 crore for 41 projects. That is about 38% of the money for about 14% of the target of ~300 projects [1][4][6] (computed).

• Later projects will get much smaller grants on average

• Round 1 gave about ₹39 crore per project on average (computed).
• About ₹2,650 crore is left for the other ~259 projects. That works out to only about ₹10 crore each [4][6] (computed).

• More first-call results are still pending, and a second call is already open [1][9]. So this average will fall further, or the ~300-project target will be missed.

• Why the money went this way: 29 of the 41 projects are later-stage, where the cap is ₹100 crore. Only 12 are early-stage, where the cap is ₹5 crore [1][4]. Later-stage clinical work costs much more, so it takes most of the budget.

• Demand is far higher than supply. 710 applications came in for the first call [5]. Even if every rupee of Component B is spent, most applicants will get nothing.

10. Would These Firms Have Done the Research Anyway?

• The strongest objection: public money is going to large, profitable companies
• 22 of the 41 projects belong to large companies, including Biocon, Sun Pharma, Zydus and Mankind Pharma [1].
• These firms already have their own R&D budgets. If a firm would have done the project anyway, the grant only adds to its profit. It does not create new research. Economists call the test for this additionality (whether public money causes research that would not have happened otherwise).

• The "₹1.9 of private money per public rupee" figure does not answer this question. It counts the firm's full share, including spending the firm may have planned already [1].

• What the objection gets right

• For a regular, non-priority later-stage project by a large firm, a 35% subsidy may simply lower costs on work already planned [4].

• The note says the 2025 amendment was meant to improve benefit-sharing [5]. But the public releases do not say what the government gets back, such as royalties, price commitments or access terms.

• Where the objection is weaker

• The six Strategic Priority projects cover dengue, TB, influenza, pneumonia/meningitis vaccines and AMR [1]. These are areas where private firms under-invest because poor patients cannot pay high prices. Here, public co-funding fixes a real market failure (a case where the market alone does not produce what society needs).

• Firms still pay 50–65% of the cost themselves [4][6], so weak projects are less likely to apply.

• Fair conclusion: the case for PRIP is strongest in the SPI areas and for start-ups. It is weakest for routine projects by big firms. DoP has published no data to show which kind of project the grant actually tipped into happening.

11. An Old Target India's Pharma Industry Has Not Met

• The research gap was identified long before PRIP
• The Pharmaceutical Research and Development Committee (PRDC) said a company should spend at least 5% of its turnover (total sales) on R&D to count as research-intensive [13].

• Indian pharma grew as the "pharmacy of the world" by making cheap generics (copies of medicines whose patents have expired). This model rewards low cost, not discovery. PRIP itself names this problem as the move from cost-based to innovation-based growth [2][4].

• The policy took years to go from report to grant

• A Parliamentary Standing Committee (46th Report) asked for an R&D policy. A High-Level Inter-departmental Committee submitted a draft in September 2020 [3].

• The first PRIP project money was announced only on 30 Sep 2026 [1]. That is about six years between the policy draft and the first grant.

• The research-institute side is still being built

• The note describes the Component A CoEs at NIPERs as sites where foundation stones were laid [7]. Industry–academia linkage (companies and universities working together) depends on these centres. They cannot produce results until the buildings, staff and equipment are ready.
• None of the Round 1 announcements names a NIPER CoE as a partner [1].

12. What Should Happen Before the Next Round

• DoP should publish what each grant actually achieved
• DoP should report each project's stage, milestones reached and private money actually spent, not only money promised. At present, the ₹3,020 crore is an expected figure [1].

• This would let Parliament's Standing Committee on Chemicals & Fertilizers check additionality. That committee's 46th Report started this policy [3].

• The Health Ministry and DoP should add a pull incentive for AMR drugs

• The UK's subscription payment model, where the NHS pays a fixed fee for access to a new antibiotic, is one working example [15].

• India's National Action Plan on AMR 2.0 is the natural home for such a guaranteed-purchase scheme [11]. It would give PRIP's antibacterial projects a buyer after approval.

• DoP should protect money for start-ups and early-stage projects in later calls

• Round 1 gave most of the money to later-stage projects [1]. Early-stage ideas are where private funding is hardest to find. A fixed share of the remaining ~₹2,650 crore (computed) for them would stop large clinical projects from using up the budget.

• DoP should make benefit-sharing terms public

• For projects funded at 50% under SPI [6], the terms on price or access for public-health programmes (such as TB and vaccine programmes) should be published. Otherwise the public cannot see what it gets for the subsidy.

13. Anchors for Answers

• Data: 41 projects, ₹1,600 crore of public assistance, ₹3,020 crore of expected private investment, ₹4,620 crore total R&D (Round 1) [1]
• Data: Round 1 used about 38% of Component B's ₹4,250 crore for about 14% of the ~300-project target (computed) [1][4][6]
• Data: 710 applications in the first call. 41 approved so far (~6%) [5][1]
• Data: Extra US$250–400 million a year is needed worldwide to sustain antibiotic development (WHO, 2024) [14]
• Report/Committee: Pharmaceutical Research and Development Committee (PRDC): 5% of turnover as the R&D-intensity benchmark [13]
• Report/Committee: Parliamentary Standing Committee on Chemicals & Fertilizers, 46th Report, which led to the High-Level Inter-departmental Committee report (Sep 2020) on pharma R&D policy [3]
• Report/Committee: WHO, Incentivising the development of new antibacterial treatments (G7 progress report, 2024) [14][15]
• Comparison: UK: NHS England pays a subscription for new antibiotics, so payment does not depend on sales volume. This is a pull incentive; PRIP is only a push incentive [15]
• Scheme: National Action Plan on AMR 2.0, the natural place for guaranteed purchase of PRIP-funded antibiotics [11]
• Scheme: PLI for pharma and medical devices, which funds manufacturing while PRIP funds R&D [10]

14. Mains Relevance

• GS-III:
• Science & Technology: developments and their applications
• Indigenisation of technology
• Industrial policy

• Investment models

• GS-II: Issues relating to the development and management of the social sector/services relating to health.

Question stems:

1. "India is the 'pharmacy of the world' by volume but not by value." Examine how schemes like PRIP seek to shift the sector towards innovation-led growth.
2. Discuss the role of public co-funding and strategic priority frameworks in addressing market failures in drug discovery for AMR, neglected tropical diseases and rare diseases.
3. Critically evaluate industry–academia linkages in India's pharma-MedTech R&D ecosystem, with reference to the NIPER Centres of Excellence.

15. Related Topics to Study Next

• National Policy on R&D and Innovation in Pharma-MedTech: launched alongside PRIP [3].
• National Action Plan on AMR 2.0: PRIP's SPI covers AMR for India-priority pathogens [11].
• National Policy for Rare Diseases: rare diseases are an SPI area [12].
• NIPERs: the host institutions for Component A CoEs [5].
• PLI schemes for pharma and medical devices: the manufacturing-side counterpart to PRIP's R&D push [10].
• Patent Mitra / MedTech Mitra: support initiatives the planned innovation exchange would link to [5].
• Neglected Tropical Diseases: a strategic priority area [1].

16. Common Errors / Trap Areas

• Wrong ministry: PRIP belongs to DoP under Chemicals & Fertilizers, not Health or DBT/DST [1].
• Confusing numbers:
• ₹5,000 crore is the scheme outlay.
• ₹11,000 crore is the target total R&D investment (about 300 projects).
• ₹1,600 crore is the first-round assistance.

• ₹4,620 crore is the first-round total R&D [1][4].

• Assistance ratio: 35% is the normal later-stage rate; 50% applies only to SPI areas. Both are capped at ₹100 crore [4][6].

• Component mix-up: Component A is infrastructure (CoEs at NIPERs); Component B is industry/start-up projects [5].
• Stage split: 29 of the 41 projects are later-stage, not early-stage [1].